APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 1:100-1:1000 |
Not tested in other applications.
Calculated MW
Predict Reactivity
Chimpanzee(>80% identity)
PROPERTIES
Form
Liquid
Buffer
PBS, 10% Glycerol
Preservative
0.01% Thimerosal
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human Tafazzin / TAZ. The exact sequence is proprietary.
Purification
Purified by antigen-affinity chromatography.
Conjugation
Unconjugated
RRID
AB_1241380
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
tafazzin , BTHS , CMD3A , EFE , EFE2 , G4.5 , LVNCX , Taz1
Cellular Localization
Isoform 1: Membrane; Single-pass membrane protein , Isoform 2: Cytoplasm , Isoform 3: Membrane; Single-pass membrane protein , Isoform 4: Membrane; Single-pass membrane protein , Isoform 5: Membrane; Single-pass membrane protein , Isoform 6: Cytoplasm , I
Background
This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq]
Database
Research Area
DATA IMAGES
![Anti-Tafazzin / TAZ antibody [C2C3], C-term used in IHC (Paraffin sections) (IHC-P). GTX106271](/templates/default/js/lightbox/images/loading.gif "Anti-Tafazzin / TAZ antibody [C2C3], C-term used in IHC (Paraffin sections) (IHC-P). GTX106271")
|
GTX106271 IHC-P Image
TAZ antibody [C2C3], C-term detects TAZ protein at cytoplasm on human placenta by immunohistochemical analysis.
Sample: Paraffin-embedded placenta.
TAZ antibody [C2C3], C-term (GTX106271) dilution: 1:100.
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
|
REFERENCE
There are currently no references for Tafazzin / TAZ antibody [C2C3], C-term (GTX106271). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Tafazzin / TAZ antibody [C2C3], C-term (GTX106271). Be the first to share your experience with this product.
![Anti-Tafazzin / TAZ antibody [C2C3], C-term used in IHC (Paraffin sections) (IHC-P). GTX106271](/upload/website/prouct_img/small/GTX106271/GTX106271_39701_CT_IHC_w_23060120_383.webp "Anti-Tafazzin / TAZ antibody [C2C3], C-term used in IHC (Paraffin sections) (IHC-P). GTX106271")
![Anti-Tafazzin / TAZ antibody [C2C3], C-term used in IHC (Paraffin sections) (IHC-P). GTX106271](/upload/website/prouct_img/normal/GTX106271/GTX106271_39701_CT_IHC_w_23060120_383.webp "Anti-Tafazzin / TAZ antibody [C2C3], C-term used in IHC (Paraffin sections) (IHC-P). GTX106271")